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1  | INTRODUC TION
Soluble IL‐33 (interleukin (IL)‐1‐like cytokine) acts as endogenous 
alarm signal (alarmin) exhibiting pleiotropic effects on surrounding 
cells and tissues. Damaged stromal cells, such as epithelial and en‐
dothelial cells, release IL‐33 from the nucleus. Besides the activation 
of Th2 immunity, soluble IL‐33 plays crucial role in barrier defence, 
and its disrupted signalling axis has been associated with asthma, 
rheumatoid arthritis, central nervous diseases and cancer.1‐3 Also, 
alarmins act to restore tissue homeostasis 4 and it might be assumed 
that IL‐33 could be involved in promotion of damaged tissue repair.
Oral cavity is frequently exposed to the growth factors and cy‐
tokines produced at the inflammation site, which coordinately act 
to restore tissue morphology and function after injury.5 The pres‐
ence of IL‐33 within the oral tissues was recently demonstrated. 
While periodontal pathogenic bacteria Porphyromonas gingivalis 
strongly stimulated IL‐33 mRNA expression in gingival epithe‐
lial cells,6 IL‐33 expression is elevated in the inflamed gingival 
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Abstract
Objectives: Soluble IL‐33 (interleukin (IL)‐1‐like cytokine) acts as endogenous alarm sig‐
nal (alarmin). Since alarmins, besides activating immune system, act to restore tissue ho‐
meostasis, we investigated whether IL‐33 exerts beneficial effects on oral stem cell pull.
Materials and Methods: Clonogenicity, proliferation, differentiation and senescence of 
stem	cells	derived	from	human	periodontal	ligament	(PDLSCs)	and	dental	pulp	(DPSCs)	
were determined after in vitro exposure to IL‐33. Cellular changes were detected by 
flow	cytometry,	Western	blot,	immunocytochemistry	and	semiquantitative	RT‐PCR.
Results: IL‐33 stimulated proliferation, clonogenicity and expression of pluripotency 
markers,	OCT‐4,	SOX‐2	and	NANOG,	but	it	inhibited	ALP	activity	and	mineralization	
in	 both	PDLSCs	 and	DPSCs.	Higher	Ki67	 expression	 and	 reduced	β‐galactosidase 
activity in IL‐33‐treated cells were demonstrated, whereas these trends were more 
conspicuous	 in	 osteogenic	medium.	However,	 after	 7‐day	 IL‐33	pretreatment,	 dif‐
ferentiation	capacity	of	IL‐33‐pretreated	cells	was	retained,	and	increased	ALP	activ‐
ity	was	observed	in	both	cell	types.	Results	showed	that	IL‐33	regulates	NF‐κB and 
β‐catenin signalling, indicating the association of these molecules with changes ob‐
served	in	IL‐33‐treated	PDLSCs	and	DPSCs,	particularly	their	proliferation,	pluripo‐
tency‐associated marker expression and osteogenesis.
Conclusions:	IL‐33	treatment	impairs	osteogenesis	of	PDLSCs	and	DPSCs,	while	in‐
creases their clonogenicity, proliferation and pluripotency marker expression. After 
exposure	to	IL‐33,	osteogenic	capacity	of	cells	stayed	intact.	NF‐κB and β‐catenin are 
implicated	in	the	effects	achieved	by	IL‐33	in	PDLSCs	and	DPSCs.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2018 The Authors. Cell Proliferation	Published	by	John	Wiley	&	Sons	Ltd
2 of 17  |     KUKOLJ et aL.
crevicular fluid7 and gingival epithelium of chronic periodontitis 
patients.8 Association of increased IL‐33 level with periodontitis 
and alveolar bone resorption and loss was also reported.8,9 Recent 
findings indicated that IL‐33 expression in cells of periapical lesion 
and radicular cyst may be involved in periapical inflammation10,11 
which is caused by the pulpal infection.12 Since the root apex and 
dental pulp are tightly interconnected tissues, communicating 
through periodontal pocket and apical foramen,12,13 during peri‐
odontal disease IL‐33 within crevicular fluid may influence dental 
pulp cells. However, despite the findings that indicate correlation 
of IL‐33 expression and periodontal inflammatory diseases, the 
involvement IL‐33 in regeneration and repair of oral tissues is not 
fully understood, particularly since there are still no data regard‐
ing the influence of IL‐33 on oral stem cells nor mode of its action.
Oral and maxillofacial tissues present highly accessible sources 
of adult progenitor/stem cells which possess features assigned to in 
vitro‐observed mesenchymal stem/stromal cell (MSC) properties, 
such as self‐renewal and multilineage differentiation.14,15 Regarding 
the heterogeneity within (craniofacial) oral stem cells populations, 
functional differences in vivo are reported. Dental MSCs, including 
exfoliated deciduous teeth stem cells (SCs), apical papilla SCs and den‐
tal	pulp	SCs	(DPSCs),	form	dentine‐like	structures	when	transplanted	
in immunocompromised mice, in contrast to periodontal ligament 
(PDL)	SCs	and	gingival	SCs	that	in	vivo	form	PDL‐like	structures.16
Dental	 pulp	 (DP)	 forms	 dentin,	 whereas	 PDL	 is	 tooth‐supportive	
connective tissue that ensures gently tooth anchorage to the alveolar 
bone, both providing tooth nutrition, protection and sensory percep‐
tion, together contributing to the tooth longevity.17‐20	Since	PDL	and	
DP	 are	 soft,	 connective	 tissues	 surrounded	 by	 hard,	 mineralized	 tis‐
sues, regulation of mineralization level is the main physiological demand 




of dynamic microenvironment, governing tissue homeostasis, differenti‐
ation and regeneration.18,21,22 Detailed understanding of functional be‐
haviour of oral MSCs, both in vitro and in vivo, is still necessary regarding 
their potential use in cellular therapy and maxillofacial reconstruction.
As previous reports indicated different protein and gene expression 
patterns	in	human	DPSCs	and	PDLSCs,24,25 in this study, we evaluated 
the	response	of	PDLSCs	and	DPSCs	to	IL‐33,	through	the	analysis	of	
their proliferation and differentiation potential. Since regulatory pro‐
teins	NF‐κB and β‐catenin are implicated in tissue immune homeostasis, 
osteogenesis and stemness maintaining,26 we also analysed the role of 
NF‐κB and β‐catenin	in	IL‐33‐mediated	effects	in	PDLSCs	and	DPSCs.
2  | MATERIAL S AND METHODS
2.1 | Isolation and cell culture of PDLSCs and DPSCs
Human	PDLSCs	and	DPSCs	were	isolated	from	healthy	patients	using	
recently described primary tissue explant techniques.27,28 Tissue 
sample	collections	of	PDL	and	DP	from	adult	teeth	were	assessed	at	
the	Department	of	Oral	Surgery	of	the	Faculty	of	Dental	Medicine,	
University of Belgrade, after getting the approval of the local ethi‐
cal	committee	and	informed	consent	of	patients.	PDL	and	DP	were	
sliced	 into	small	pieces	and	cultured	 in	growth	medium	 (GM)	con‐
taining Dulbecco’s modified Eagle’s medium (DMEM, Sigma‐Aldrich, 
St.	Louis,	MO,	USA)	with	10%	foetal	bovine	serum	(FBS,	Capricorn‐
Scientific,	 Ebsdorfergrund,	 Germany),	 100	U/mL	 penicillin	 and	
100	µg/mL	streptomycin	(Gibco,	Thermo	Fisher	Scientific).	Standard	
cultivation	 conditions	were	 as	 follows:	 37°C	 in	 humidified	 atmos‐
phere containing 5% CO2 with twice a week medium exchange. The 
outgrown	cells	were	detached	using	0.25%	trypsin/EDTA	(Gibco).	All	
experiments	were	performed	using	PDLSCs	and	DPSCs	subcultured	




bovine serum albumin (BSA; Sigma‐Aldrich) in phosphate‐buffered 
saline	 (PBS,	Capricorn,	Germany).	Then,	 cells	were	 incubated	with	
fluorescein	isothiocyanate	(FITC)‐	or	phycoerythrin	(PE)‐conjugated	
antibodies	 against	 antigens	 CD44H,	 CD73,	 CD90	 (R&D	 Systems,	
Minneapolis, MN, USA), CD105, HLA‐DR (Invitrogen, Carlsbad, CA, 
USA) and CD34 (DakoCytomation, Denmark) during 30 minutes in 
the	 dark	 at	 4°C.	 Flow	 cytometry	 was	 performed	 using	 Cytomics	
FC	 500	 (Beckman	 Coulter,	 Brea,	 CA,	 USA)	 cytometer,	 while	 data	
were analysed using WinMDI 2.9 software (J. Trotter, The Scripps 
Research Institute, La Jolla, CA).
2.3 | Cellular viability




Aldrich) was added. Optical density of formazan crystals dissolved 
with isopropanol was detected at 540 nm by microtitre plate reader 
(LabSystems	Multiskan	PLUS,	Finland).
2.4 | In vitro osteogenic differentiation
Cells were seeded in 96‐well plates (5000 cells/well) and grown in 
GM	 in	 standard	 conditions	 until	 the	 confluency.	 Then,	 the	 osteo‐
genic differentiation medium (OM) was added with or without IL‐33 
(100	ng/mL).	For	analysis	of	effect	of	 IL‐33	pretreatment,	PDLSCs	
and	DPSCs	were	cultivated	in	GM	with	or	without	IL‐33	(100	ng/mL)	
during	7	days,	 and	 subsequently	only	 in	OM	 for	 appropriate	 time.	
Osteogenesis	was	detected	after	7	(alkaline	phosphatase‐ALP	stain‐
ing assay) and 14 days of cultivation (Alizarin red staining) in OM 
that	contained	GM	with	5%	FBS,	50	μM ascorbic acid‐2‐phosphate 
(Sigma‐Aldrich) and 10 mM β‐glycerophosphate (Sigma‐Aldrich). 
Enzyme	activity	and	histochemical	staining	of	ALP	and	extracellular	
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matrix mineralization by Alizarin red staining were estimated as pre‐
viously described.29 Light microscope (Olympus, Japan) was used to 
capture cells, while the mineralization level was quantified by den‐
sitometry in NIH—ImageJ software (LOCI, University of Wisconsin, 
Madison, WI, USA).
2.5 | Cellular clonogenicity, proliferation and 
senescence in osteogenic differentiation settings
Colony‐forming	unit‐fibroblast	(CFU‐F)	assay	was	performed	as	we	
previously	 described	 for	 PDLSCs	 and	 DPSCs.27,28	 CFU	 efficiency	
was determined as the percentage of colonies relative to total num‐
ber of seeded cells in each well.
To	determine	ALP+	CFU‐Fs,	termed	as	CFU‐osteoblasts	(CFU‐O),	
cells were seeded in 24‐well plates at concentration 100 cells/well 
and	cultivated	in	GM	in	standard	conditions	during	7	days.30 Then, 
the	OM	was	added	and	incubation	was	continued	for	the	next	7	days	
with or without IL‐33 (100 ng/mL) when the colonies were stained 
for	 ALP	 activity.	 Percentage	 of	 CFU‐O	was	 expressed	 as	 ratio	 of	
ALP‐positive	CFUs/total	CFUs*100.
Following	the	IL‐33	(100	ng/mL)	during	7‐day	osteogenic	induc‐
tion cell number, expression of intracellular proliferation marker 
Ki67	and	β‐galactosidase activity were estimated. Cell number was 
determined by Trypan blue exclusion test.
Percentage	of	Ki67‐positive	cells	was	determined	by	flow	cytom‐
etry equipment (as for surface marker detection). Cells were washed 
with	PBS,	fixed	in	5%	formaldehyde	and	permeabilized	in	0.5%	BSA/
PBS	containing	0.1%	Triton	X‐100.	Following	the	nonspecific	block‐




For	 single‐cell	 β‐galactosidase staining, cells were seeded at 
concentration 2 × 103 cells/well in 96‐well plates, adhered during 
6 hours, and stained using Senescence Cells Histochemical Kit 
(Sigma‐Aldrich). The single‐stained cells were captured and counted 
under light microscope, and the percentage of stained cells was de‐
termined for several separated visual fields.
2.6 | Western blot
After cultivation with IL‐33 (100 ng/mL) at different time points, 
total protein extracts were isolated using lysis buffer. Same amounts 
of protein samples (concentration determined by BCA assay, Serva, 
Germany)	 were	 separated	 by	 SDS‐PAGE	 and	 electrotransfered	
onto	nitrocellulose	membrane	Hybond	ECL	(AppliChem,	Germany).	
Next, membranes were blocked in 4% nonfat milk (Serva) in TBST 
for 1 hour and subsequently incubated with primary antibodies: 
mouse	 anti‐GAPDH,	 anti‐NF‐κB and anti‐β‐catenin (Santa Cruz 
Biotechnology)	 overnight	 at	 4°C.	 Protein	 bands	 were	 visualized	
using	ECL	reagent	(Serva,	Germany)	after	membrane	incubation	with	
anti‐mouse	HRP‐conjugated	antibody	(Sigma‐Aldrich)	during	1	hour	
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2.7 | Immunofluorescence
Cells were seeded in 24‐well plates over coverslips (1 × 103 cells/well) 
and	treated	as	described	 in	Figure	 legend.	Then,	cells	were	fixed	 in	
4%	 paraformaldehyde,	 permeabilized	 in	 0.1%	 Triton	 X‐100	 in	 PBS,	
blocked	with	3%	BSA/PBS	and	stained	with	primary	antibodies:	rab‐
bit	anti‐Ki67	(Abcam),	mouse	anti‐NF‐κB (Santa Cruz Biotechnology), 
mouse anti‐β‐catenin (Santa Cruz Biotechnology), mouse anti‐
NANOG,	 rabbit	 anti‐Oct‐4	 and	 mouse	 anti‐SOX‐2	 (Cell	 Signaling	
Technology,	Danvers,	MA,	USA).	Samples	incubated	in	3%	BSA/PBS	
only	 represented	negative	 controls	 (Supplementary	Figure	S3).	The	
corresponding	 FITC‐coupled	 secondary	 antibodies	 (Sigma‐Aldrich)	
and	1	ng/mL	of	nuclear	dye	DAPI	(Sigma‐Aldrich)	were	added	during	
2 hours. Samples were examined using an epi‐fluorescent microscope 
(Olympus, Japan).
2.8 | Semiquantitative RT‐PCR
After 24 hours of IL‐33 (100 ng/mL) treatment, total RNA was ex‐
tracted using TRIzol Reagent (Invitrogen) and cDNA was synthesized 
from	200	ng	of	total	RNA	by	RevertAidTM	H	Minus	First	Strand	cDNA	
Synthesis	Kit	(Thermo	Scientific,	Waltham,	MA).	Template	PCRs	were	
performed after 33 cycles of amplification with adjusted annealing 
temperature.	Primer	NIH	 sequences,	 corresponding	 annealing	 tem‐
peratures and the amplified product lengths are provided in Table 1.
2.9 | Statistical analysis
Intensities	 of	 immunoblots	 and	 RT‐PCR	 bands	 were	 determined	
by ImageMaster TotalLab v1.11 software (Amersham Biotech). 
Statistical significances (*P < 0.05) were determined by Student’s 
t	 test.	 Data	 were	 analysed	 and	 graphed	 using	 GraphPad	 Prism	 6	
Software (San Diego, CA).
3  | RESULTS
3.1 | Mesenchymal stem/stromal cell features of 
PDLSCs and DPSCs: Effects of IL‐33
By	using	MTT	test,	we	examined	viability	of	PDLSCs	and	DPSCs	in	
the presence of increasing concentrations of IL‐33 at different time 












without changing subcellular localization of these transcriptional 
factors,	 in	both	cell	types.	In	PDLSCs	and	DPSCs,	OCT‐4	localized	
in cytoplasm and nuclear region, while IL‐33 increased its expres‐
sion	 in	 both	 compartments.	 In	 contrary	 to	 PDLSCs,	where	 SOX‐2	
was	predominantly	 in	nuclear	 region,	 in	DPSCs	SOX‐2	was	mostly	




3.2 | IL‐33 modulates colony‐forming efficiency and 
early osteogenesis in PDLSCs and DPSCs















ing	 their	 basal	 ALP	 activity	 in	GM.	 Compared	 to	DPSCs,	 PDLSCs	
showed	significantly	higher	ALP	activity	 (Figure	2C	and	2D).	 IL‐33	
did	not	alter	Runx2	and	ALP	gene	expression	 level	 in	PDLSCs	and	
DPSCs,	 while,	 compared	 to	 DPSCs,	 PDLSCs	 showed	 significantly	
higher expression of both molecules in the absence or presence of 
IL‐33	(Figure	2E).	On	contrary,	both	IL‐33‐pretreated	cell	types	pos‐
sessed	significantly	increased	ALP	activity	in	GM	as	well	as	in	OM,	
while	 the	 level	 of	ALP	 activity	was	 significantly	 higher	 in	PDLSCs	
than	in	DPSCs	(Figure	2F	and	2G).
F I G U R E  1  Viability,	morphology	and	phenotype	of	cultivated	PDLSCs	and	DPSCs	in	the	presence	of	IL‐33.	A,	Metabolic	activity	
of	cells	treated	with	IL‐33	(5,	10,	20,	50	and	100	ng/mL)	during	24,	48,	72	and	120	h	estimated	by	using	MTT	assay.	B,	Fibroblast‐like	
morphology	of	PDLSCs	and	DPSCs.	Cells	were	grown	in	GM	in	the	presence	or	absence	of	IL‐33	(100	ng/mL)	for	72	h.	Scale	bars:	50	μm. C, 
Immunophenotype of cells determined by flow cytometry. Representative histograms show the percentage of positive cells (empty peaks) 
versus	isotype	controls	(shaded	peaks).	D,	Expression	of	pluripotency‐related	transcription	factors:	Oct4,	SOX‐2	and	NANOG	detected	by	
indirect	immunofluorescence	staining	with	FITC‐conjugated	corresponding	secondary	antibodies	(Scale	bars:	20	μm). DNA was stained with 
DAPI.	Results	are	presented	as	mean	±	SEM	of	three	different	samples	(n	=	3)	from	at	least	three	independent	experiments
     |  5 of 17KUKOLJ et aL.
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3.3 | Effects of IL‐33 treatment and pretreatment 
on the late osteogenesis
Alizarin red staining of deposited mineralized matrix in the dif‐
ferentiating cultures revealed that IL‐33 treatment significantly 
reduces the calcification level achieved in OM in both cell types, 
while no sign of mineralization was detected in the cells culti‐
vated	 in	GM	 (Figure	3A	and	B).	Unlike	 the	 inhibition	of	miner‐
alization during IL‐33 treatment, IL‐33‐pretreated cells achieved 
mineralization, at the similar level as observed in untreated cells 
(Figure	 3C	 and	 D).	 IL‐33	 treatment,	 as	 well	 as	 IL‐33	 pretreat‐
ment, did not affect chondrogenic nor adipogenic differentia‐
tion	potential	of	both	cell	types	(Supplementary	Figure	S2,	Data	
S1).
These results indicated a complex role of IL‐33 in the regulation 
of	 PDLSCs	 and	 DPSCs	 differentiation.	 Although	 IL‐33	 can	 inhibit	
early and late osteogenesis when present simultaneously with the 
specific	differentiation	stimuli,	pre‐exposure	of	PDLSCs	and	DPSCs	
to this cytokine does not affect their osteogenic differentiation 
potential.
F I G U R E  2  Cellular	clonogenicity	and	ALP	activity	of	cultivated	PDLSCs	and	DPSCs	in	the	presence	of	IL‐33	in	osteogenic	differentiation	







the absence of IL‐33 by t	test:	*P	<	0.05;	**P	<	0.01;	or	in	comparison	with	OM	in	the	absence	of	IL33:	*P	<	0.05	or	between	PDLSCs	and	




difference	in	comparison	with	GM	in	the	absence	of	IL‐33	by	t	test:	**P	<	0.01;	***P < 0.01; or in comparison with OM in the absence of 




F I G U R E  3  Effect	of	IL‐33	treatment	and	pretreatment	on	osteogenic	differentiation	capacity	of	PDLSCs	and	DPSCs.	Osteogenic	
differentiation detected after 14 d using Alizarin red (Scale bars: 50 µm), quantification of Ca depositions. Representative photographs are 
shown.	(A,B),	Cells	were	cultured	in	GM	and	OM	with	or	without	IL‐33	(100	ng/mL).	Results	in	graphs	are	presented	as	mean	±	SEM	from	
at	least	three	independent	experiment.	Statistically	significant	differences	in	comparison	with	GM	in	the	absence	of	IL‐33	(set	as	1)	by	t 
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3.4 | Effects of IL‐33 on cell proliferation and  
β‐galactosidase activity in osteogenic settings
IL‐33	significantly	increased	only	the	proliferation	of	PDLSCs	in	GM.	




marker	 Ki67	 expression	 within	 IL‐33‐treated	 PDLSCs	 and	 DPSCs	
in	GM,	as	well	 as	 in	OM,	 showed	high	percentage	of	Ki67‐positive	
cells	(over	92%	per	cent)	in	all	examined	groups	(Figure	4B).	Cellular	




cell cytoplasm in basal conditions, while IL‐33 stimulated expression 
of	Ki67	in	perinuclear	and	cytoplasmic	region	in	both	cell	types	in	the	
presence	or	absence	of	OM.	In	PDLSCs,	the	OM	itself	elevated	Ki67	









DPSCs:	##P < 0.01; ###P	<	0.001	B,	Flow	cytometric	detection	of	proliferation‐associated	protein	Ki67.	Representative	histograms	showing	
the	percentage	of	Ki67‐positive	cells	(empty	peaks)	in	comparison	with	unstained	cells	as	negative	control	(grey	peaks)	C,	Cellular	localization	
of	Ki67	determined	by	immunofluorescence	(Scale	bars:	20	µm).	DNA	was	stained	with	DAPI.	D,	Detection	of	single	β‐galactosidase‐positive 
cells. Representative photographs are shown (Scale bars: 200 μm). E, Number of single β‐galactosidase‐positive cells counted per 2000 
cells/well	in	96‐well	plate.	Results	in	graphs	are	presented	as	mean	±	SEM	of	three	different	samples	(n	=	3)	from	at	least	three	independent	
experiments.	Statistically	significant	differences	in	comparison	with	GM	in	the	absence	of	IL‐33	control	(set	as	1)	by	t	test:	**P < 0.01; 
***P	<	0.001;	or	in	comparison	with	OM	in	the	absence	of	IL‐33:	**P < 0.01.
F I G U R E  5   IL‐33‐modified	NF‐κB and β‐catenin	signalization	in	PDLSCs	and	DPSCs.	Cells	were	cultivated	in	GM	with	IL‐33	(100	ng/






Representative images of three experiments are shown
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The presence of IL‐33 significantly decreased number of β‐galac‐
tosidase‐positive	PDLSCs	and	DPSCs	in	GM.	Also,	OM	significantly	
reduced β‐galactosidase positivity in both cell types, while IL‐33 ad‐
ditionally	significantly	supported	this	effect	in	PDLSCs	and	slightly	
in	DPSCs	(Figure	4D).
These results indicate that both cell types are highly pro‐
liferative in in vitro conditions and that minor part of their 
populations	persists	in	resting	cell	state	G0.	OM	increased	cell	
proliferation	and	Ki67	expression	and	 reduced	β‐galactosidase 
activity, while IL‐33 additionally supported these effects. We 
supposed that the effects observed in early osteogenesis, the 
decreased	ALP	activity,	did	not	occur	due	to	 inhibition	of	pro‐
liferation	 nor	 senescence	 induction	 by	 IL‐33	 in	 PDLSCs	 and	
DPSCs.
3.5 | IL‐33‐affected NF‐κB and β‐catenin expression 
in PDLSCs and DPSCs




that IL‐33 significantly inhibited β‐catenin expression after 24 hours in 
PDLSCs,	while	in	DPSCs,	IL‐33	significantly	elevated	β‐catenin expres‐
sion	after	30	minutes,	60	minutes	and	24	hours	(Figure	5B).
The	 analysis	 of	 NF‐κB and β‐catenin localization showed that 
after	72	hours	of	stimulation	with	IL‐33,	 in	PDLSCs	NF‐κB expres‐
sion was increased in the nuclear region. Nuclear localization of 
NF‐κB	 was	 also	 observed	 in	 DPSCs	 after	 IL‐33	 treatment,	 but	 in	




independent	experiments.	Statistically	significant	difference	in	comparison	with	GM	in	the	absence	of	IL‐33	by	t	test:	*P	<	0.05;	**P < 0.01; 
***P < 0.001; or in comparison with IL‐33 treatment: ##P < 0.01; ###P < 0.001








set as 1) by t	test:	*P	<	0.05;	**P	<	0.01;	***P < 0.001; or in comparison with IL‐33 treatment: #P < 0.05
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lesser	 extent	 than	 in	 PDLSCs	 (Figure	 5C).	 On	 the	 other	 side,	 the	
presence of IL‐33 stimulated expression of β‐catenin in nucleus of 
both	PDLSCs	and	DPSCs	(Figure	5C).	Obtained	data	imply	that	IL‐33	
regulates total protein expression level and importantly, subcellular 
localization	of	NF‐κB and β‐catenin	in	PDLSCs	and	DPSCs.
3.6 | Roles of NF‐κB and β‐catenin in IL‐33‐
mediated PDLSCs and DPSCs proliferation
To	evaluate	 involvement	of	NF‐κB and β‐catenin in IL‐33‐elevated 
proliferation	of	PDLSCs	 and	DPSCs,	 in	 both	basal	 and	osteogenic	
conditions	 (Figure	 3A)	 we	 included	 two	 chemical	 inhibitors,	 am‐
monium	pyrrolidinedithiocarbamate	(PDTC,	2	µM,	Tocris)	as	NF‐κB 
inhibitor and 2‐phenoxybenzoic acid‐[(5‐methyl‐2‐furanyl)methyl‐
ene]	 hydrazide	 (PNU	 74654,	 5	µM,	 Sigma‐Aldrich)	 which	 binds	 β‐
catenin	and	 inhibits	Wnt	signalling.	The	presence	of	PDTC	slightly	
increased basal proliferation, while not changing IL‐33 increased 
proliferation	 in	 PDLSCs	 in	GM.	PNU	 inhibitor	 increased	 prolifera‐
tion	 of	 PDLSCs	 in	 GM,	while	 abolished	 IL‐33‐stimulated	 PDLSCs’	
proliferation	(Figure	6A).	 In	OM,	with	or	without	 IL‐33,	PDTC	only	









3.7 | Involvement of NF‐κB and β‐catenin in IL‐33‐
stimulated pluripotency‐associated marker expression
Results	obtained	for	PDLSCs	showed	that	PDTC	inhibitor	abolished	
OCT‐4A protein expression in the absence and presence of IL‐33, 
while	PNU	abrogated	IL‐33‐stimulated	OCT‐4A	protein	expression	
without affecting basal OCT‐4A expression in these cells. However, 
IL‐33 significantly stimulated Oct‐4A and Oct‐4B mRNA expression, 
while	the	presence	of	PDTC	and	PNU,	although	not	affecting	basal	
OCT‐4A and Oct‐4B mRNA expression, failed to alter IL‐33‐stimu‐
lated	OCT‐4A.	On	the	other	side,	PDTC	abolished	IL‐33‐stimulated	
Oct‐4B	mRNA	expression	in	PDLSCs.	As	for	the	SOX‐2	expression	







experiments. Statistically significant differences in comparison with control (untreated cells, set as 1) by t	test:	***P < 0.001; or in comparison 
with IL‐33 treatment: ###P < 0.001
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mRNA	 expression	was	 reduced.	 PNU	 inhibitor,	 also	 favoured	 nu‐
clear	localization	of	NANOG	protein	in	the	presence	of	IL‐33,	slightly	
stimulating	 basal	NANOG	protein	 expression.	 The	 basal	NANOG	




protein	expression	 in	PDLSCs.	mRNA	analysis	 indicated	 that	only	
PDTC	decreased	IL‐33‐stimulated	mRNA	expression	of	Oct‐4B.
The	same	analysis	performed	for	DPSCs	demonstrated	that	IL‐33	
increased OCT‐4 protein expression in cytoplasm and nuclear region. 
The	PDTC	inhibitor	itself	only	slightly	stimulated	OCT‐4	protein	ex‐
pression,	but	diminished	 its	 IL‐33‐increased	expression.	PNU	inhib‐
itor stimulated basal, without affecting the IL‐33‐stimulated OCT‐4 








mRNA expression, however, not altering the stimulated expression 
by	 IL‐33.	The	basal	NANOG	protein	expression	was	also	 increased	
by	 the	 presence	 of	 both	 inhibitors	 in	 the	 culture.	 However,	 PDTC	
and	PNU	inhibited	the	IL‐33‐stimulated	NANOG	protein	expression	
mostly in cytoplasm. At the mRNA level, although both inhibitors did 
not	change	IL‐33‐increased	NANOG	mRNA	expression,	PDTC	did	not	
alter,	while	PNU	inhibitor	increased	basal	NANOG	mRNA	expression	
in	DPSCs	 (Figure	7B).	 In	 general,	 PDTC	diminished	 IL‐33‐increased	
protein	expression	of	OCT‐4A,	SOX‐2	and	NANOG,	while	PNU	at‐
tenuated	 IL‐33‐stimulated	 SOX‐2	 and	 NANOG	 protein	 expression.	
Except	Oct4B	mRNA	which	was	decreased	by	PNU,	inhibitors	did	not	
alter IL‐33‐increased pluripotency marker gene expression.
3.8 | Roles of NF‐κB and β‐catenin in IL‐33‐affected 
osteogenesis
Our results showed that inhibitors’ presence accomplished similar 
effects	in	PDLSCs	(Figure	8A,	B)	and	DPSCs	(Figure	8D,	E).	Namely,	
PDTC	and	PNU	inhibitors	restored	IL‐33‐reduced	ALP	activity	and	
Ca deposition levels in both cell types, without affecting the basal 
osteogenic	differentiation	(Figure	8A,	B,	D,	E).	Surprisingly,	RT‐PCR	
results	did	not	reveal	any	significant	effect	of	the	presence	of	PDTC	
and	 PNU	 on	 Runx2	 and	ALP	 gene	 expression	which	 stayed	 unaf‐
fected	after	IL‐33	treatment	in	both	cell	type	(Figure	8C,	F).
4  | DISCUSSION
The goal of this study was to evaluate the in vitro effects of IL‐33 
on	main	functional	properties	of	PDLSCs	and	DPSCs,	by	addressing	
their basal stemness‐related features, such as colony‐forming capac‐
ity, proliferation, expression of pluripotency‐associated markers and 
differentiation, especially referring to osteogenesis.
The	PDLSCs	and	DPSCs	used	in	our	study,	as	resident	population	
of progenitor cells of periodontal ligament and dental pulp, share 
characteristics with the bone marrow mesenchymal stem/stromal 
cells (BM‐MSC), such as their colony‐forming capacity,in vitro tri‐
lineage differentiation and surface markers expression.31 Although 
PDLSCs	 and	 DPSCs	 share	 close	 anatomical	 location,	 differences	
between these cells were observed in mineral composition genera‐
tion,32 stability after ectopic transplantation,33 hard tissue formation 
and alkaline phosphatase activity,34 proteome24 and gene expres‐
sion.35	As	PDLSCs	and	DPSCs	respond	to	specific	stimuli	triggered	
by inflammation or injury, which affect cell recruitment and prolif‐
eration in dental regions,36 it is probable that their responsiveness 
to the microenvironment stimuli may be different. Release of IL‐33 
in periodontal ligament caused by tooth movement in mice model 
regulates alveolar bone remodelling, inhibiting differentiation of os‐
teoclasts and stimulating osteoblast accumulation.37 Although IL‐33 
is recognized as important cytokine in bone physiology, its effects 
on human dental stem cells functionality are still unknown.
Our results demonstrated that IL‐33 cytokine did not alter the vi‐
ability	nor	the	immunophenotype	of	both	PDLSCs	and	DPSCs,	while	
DPSCs	expressed	lower	growth	rate	in	comparison	with	PDLSCs	in	
all passages, as it was also reported.24 Both investigated cell types 
maintained their growth rate during prolonged in vitro culture, as 
it has previously been revealed.38	Since	PDL	and	DP	inhabit	in	soft	
connective tissues surrounded by hard, mineralized tissues, the reg‐
ulation of cell mineralization/osteogenesis level is the main physio‐
logical demand within these tissues. To evaluate effects of IL‐33 on 
PDLSCs	and	DPSCs	proliferation	and	osteogenic	differentiation,	we	
adjusted our experimental settings to quantify the cell number and 
the	 efficiency	 of	 CFU‐Fs,	 as	well	 as	 the	 efficiency	 of	 ALP+	 CFUs,	
called	CFU‐Os,	colonies	containing	osteoblast	 lineage	progenitors.	
We	found	that	IL‐33	stimulates	CFU‐F	clonogenicity	of	dental	stem	







ulation contains higher frequency of osteoblast lineage progenitors 
than	DPSCs,	while	the	significantly	higher	number	of	the	total	CFU‐
Fs	may	be	related	to	higher	proliferation	rate	of	PDLSCs.	Since	the	
size of osteoblastic precursor pool in mouse BM‐MSC plays import‐
ant role in regulating bone formation and resorption,39 our results 
point to possible differences in osteogenic commitment between 
PDLSCs	 and	 DPSCs.	 In	 our	 study,	 IL‐33	 presence	 impaired	 ALP	
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activity	and	mineralization	levels	in	PDLSCs	and	DPSCs,	while	7‐day	
IL‐33‐pretreated cells showed increased basal, as well as induced 
ALP	activity	and	restored	mineralization.	Even	we	detected	differ‐
ences	 in	 ALP	 activity,	we	 did	 not	 found	 any	 significant	 change	 in	
Runx2	and	ALP	mRNA	expression	after	IL‐33	stimulation	in	PDLSCs	
and	DPSCs.	Osteogenesis‐related	effects	of	Runx2	and	ALP	are	time	
and concentration dependent.40 The actions of the Runx2 gene may 
be mediated by upregulation of protein levels and/or activation of 
the Runx2 transcript, while osteogenesis is predominantly associ‐
ated with increased Runx2 activity, without a change in mRNA or 
protein levels.41,42 As IL‐33 can stimulate activation of mitogen‐acti‐
vated protein kinases in dental stem cells (our unpublished data), it is 
possible that Runx2 phosphorylation might be involved in regulation 
of its activity instead of gene expression.41,43 We anticipate that ad‐
ditional analysis of IL‐33 effects on osteogenic markers is necessary, 
to reveal protein and genes expression/activities in a wider time 
range.
Stimulatory	 effect	 of	 IL‐33	 on	 the	 proliferation	 of	 PDLSCs	
and	 DPSCs	 was	 accompanied	 by	 sustained	 high	 Ki67	 positivity	




different but comparable to those reported for rat BM‐MSC44 or 
adipose tissue stem cells,45	 where	 >80%	 or	 >70%	 of	 Ki67‐posi‐
tive	were	found,	respectively.	As	Ki67	is	expressed	in	all	cell	cycle	
phases	except	G0,	 it	 can	be	concluded	 that	majority	of	PDLSCs	
and	 DPSCs	 (≥90%)	 are	 actively	 dividing	 cells,	 indicating	 their	
function as immature osteoprogenitors, where their proliferation 
significantly contributes to bone tissue remodelling phase.46 Our 
study	revealed	predominantly	Ki67	cytoplasmic	staining	in	dental	
stem cells and similar was found in ASCs.45 Since there are few 
evidences	regarding	Ki67	expression	in	dental	stem	cells,	it	would	
be reasonable to find out precise biological role of nuclear and 
cytoplasmic	Ki67.
Activation	 of	NF‐κB by IL‐33 has been shown in different cell 
types, such as fibroblast‐like synoviocytes,47 endothelial cells48 and 
human HEK293RI cells.49 Here, for the first time, we showed that 
IL‐33	stimulated	activation	of	NF‐κB	in	PDLSCs	and	DPSCs.	The	ob‐
served	IL‐33	increased	proliferation	of	DPSCs,	achieved	via	NF‐κB 
activation, when cultivated in the presence of osteogenic stimuli, is 
in agreement with previous report demonstrating that inflammatory 
cytokine	IFN‐γ‐promoted	DPSC	proliferation	via	NF‐κB.50 Observed 
involvement	of	NF‐κB	activation	in	the	inhibition	of	ALP	activity	and	
matrix mineralization achieved by IL‐33 treatment were also in ac‐
cordance	with	previously	reported	data	for	PDLSCs51	and	DPSCs.50 
The β‐catenin, as part of canonical Wnt signalling, controls neural 
stem cell proliferation52 and has important role in tooth biology.53 
Here,	IL‐33‐elevated	proliferation	of	PDLSCs	was	achieved	by	β‐cat‐
enin	 activation,	 but	 also	 the	 inhibitory	 effects	 of	 IL‐33	on	PDLSC	
and	 DPSC	 osteogenesis.	 Previous	 contradictory	 reports	 regard‐
ing β‐catenin‐mediated promotion of osteogenic differentiation of 
PDLSCs53,54	 on	one	 side	and	 suppression	of	DPSC	osteogenesis55 
on the other imply that the role of β‐catenin signalling in osteogen‐
esis is not fully comprehended. However, inhibition of osteogenic 
differentiation	is	mediated	through	NF‐κB activation, which further 
on promoted β‐catenin ubiquitination and degradation in human and 
mouse MSCs.56 Therefore, it can be assumed that cooperation of 
NF‐κB and β‐catenin may exist and be involved in regulation of den‐
tal stem cell functions, too.
We found that IL‐33 decreased β‐galactosidase	activity	in	PDLSCs	
and	 DPSCs	 simultaneously	 with	 stimulation	 of	 their	 proliferation	
capacity. The inhibition of β‐galactosidase activity was additionally 
strengthened in OM, which can independently reduce β‐galactosi‐
dase activity in both cell types. Important stimulator of osteogenesis 
in OM, ascorbic acid‐2‐phosphate increases proliferative capacity by 
attenuating senescence and expression of reactive oxygen species 
in human osteoarthritic osteoblast.57 Whether the antioxidative ef‐
fect is also mechanism of the action of IL‐33 needs to be further in‐
vestigated.	Promotion	of	cell	divisions	and	increased	ALP	activity	in	
human and mouse BM‐MSCs could be the mechanism through which 
reduction in senescence can be achieved.58 However, our data indi‐
cated that the inhibitory effect of IL‐33 treatment on osteogenesis 
was not achieved through antiproliferative or pro‐ageing mechanism.
Important outcome from our study is the observation that IL‐33 
stimulated protein and gene expression of pluripotency‐associated 
markers,	OCT4,	SOX‐2	and	NANOG	in	both	cell	populations	inves‐
tigated. Much of the research up to now has been descriptive in na‐
ture	of	significance	of	these	markers	expression	in	MSC	biology.	For	
our knowledge, there is no evidence about the influence of IL‐33 on 
stemness genes in primary progenitors. However, studies showed 
that IL‐33 supported stemness in breast59 and colorectal60 cancer 
cell types, through stimulation of pluripotency marker expression. 
Human	PDLSCs	and	DPSCs	retain	stemness	genes	and	proliferation	
for prolonged time during in vitro cultivation,38 and expression of 
stemness markers was often associated with their origin from neural 
crest (stem) cells which migrate and establish stem cell pools through 
the anatomical sites such as dental region or even bone marrow.61,62 
Our	previous	study	demonstrated	that	DPSCs	and	PDLSCs	express	
pluripotency markers in higher extent than other adult stem cells, 
such as adipose tissue progenitors.63 The elevated pluripotency 
marker expression accompanied with IL‐33‐stimulated prolifer‐
ation	 and	 clonogenicity	 of	 PDLSCs	 and	 DPSCs	 is	 in	 accordance	
with previous studies demonstrating overexpression of OCT‐4A,64 
SOX‐265	 and	NANOG66 associated with increased proliferation of 
DPSCs	or	clonogenic	capacity	of	human	BM‐MSCs.67 Liu et al also 
reported	that	OCT‐4A	overexpression	in	DPSCs	leads	to	upregula‐
tion	of	other	pluripotency	genes,	such	as	Oct4B1,	SOX‐2,	NANOG,	
Klf4 and c‐Myc, thus indicating possible close mutual cooperation 
of these transcriptional factors.64 Contrary to OCT‐4A, the role of 
OCT4B in pluripotency is not clear. However, it may be assumed 
that OCT4B actually governs self‐renewal and maintenance of tis‐
sue homeostasis within adult tissues.68	Previous	studies	 indicated	
that OCT4B might be involved in cellular stress response69 and 
antiapoptotic activity in cancer cells.70,71 Importantly, OCT4B may 
indirectly be increased in dental pulp tissues and dental pulp cells 
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exposed to proinflammatory factors, where it has been suggested 
that OCT4B represents a antiapoptotic mediator and subsequently 
may be the important factor in dental regeneration.72 Our results in‐
dicate that IL‐33 increases expression of OCT4B mRNA expression 
in	both	PDLSCs	and	DPSCs.	Whether	IL‐33‐stimulated	OCT4B	has	
some regulatory role in dental stem cell phenotype and behaviour 
needs	to	be	additionally	investigated.	Previously,	the	role	of	NF‐κB 
signalling	in	maintenance	of	pluripotency	of	human	iPSC	was	shown,	
as	the	augmented	NF‐κB activity correlated with increased expres‐
sion	of	OCT‐4A	and	NANOG,	sustaining	human	iPSC	in	undifferen‐
tiated state.73	Our	analysis	also	showed	that	the	activation	of	NF‐κB 
is	 involved	 in	 IL‐33‐upregulated	 Oct4	 and	 NANOG	 expression	 in	
PDLSCs	and	Oct4,	SOX‐2	and	NANOG	in	DPSCs.	Additionally,	IL‐33‐
mediated β‐catenin	activity	stimulated	Oct4A,	Oct4B	and	NANOG	
expression	 in	PDLSCs,	 and	Oct4B,	SOX‐2	and	NANOG	 in	DPSCs.	
The important role of β‐catenin in regulating expression of stemness 
markers in embryonic stem cells74 and human BM‐MSCs75 was also 
shown.	Although	SOX‐2	is	involved	in	the	suppression	of	osteogenic	
differentiation of human osteoblast cell line via β‐catenin activity,76 
the roles of pluripotency markers beside self‐renewal regulation are 
still not clarified.
In summary, our study brings new evidence about the effects of 
IL‐33 on dental stem cell functions. It can be concluded that IL‐33 
treatment	 impairs	PDLSC	and	DPSC	osteogenesis,	 favouring	 their	
proliferation and clonogenicity, but not diminishing their differenti‐
ation potential. These findings suggest that IL‐33 might delay dental 
stem cell pool exhaustion caused by activation stimuli, triggered by 
inflammation or stress, which initiate their functional response.
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